West Pharmaceutical Services (WST) reported Q3 adjusted earnings Thursday of $1.85 per diluted share, down from $2.16 a year earlier.
Analysts polled by Capital IQ expected $1.49.
Revenue for the quarter ended Sept. 30 was $746.9 million, compared with $747.4 million a year earlier.
Analysts surveyed by Capital IQ expected $709.6 million.
The company increased its 2024 adjusted EPS guidance to now be between $6.55 and $6.75 from the prior outlook of $6.35 to $6.65. Analysts polled by Capital IQ expect $6.41.
Net sales for the year are projected to be about $2.88 billion to about $2.91 billion, compared with a prior range of $2.87 billion to $2.90 billion. Analysts surveyed by Capital IQ expect $2.87 billion.
Price: 306.21, Change: +19.77, Percent Change: +6.90
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.